Details

Autor(en) / Beteiligte

• Balmaña, Judith
• Fasching, Peter A.
• Couch, Fergus J.
• Delaloge, Suzette
• Labidi-Galy, Intidhar
• O’Shaughnessy, Joyce
• Park, Yeon Hee
• Eisen, Andrea F.
• You, Benoit
• Bourgeois, Hughes
• Gonçalves, Anthony
• Kemp, Zoe
• Swampillai, Angela
• Jankowski, Tomasz
• Sohn, Joo Hyuk
• Poddubskaya, Elena
• Mukhametshina, Guzel
• Aksoy, Sercan
• Timcheva, Constanta V.
• Park-Simon, Tjoung-Won
• Antón-Torres, Antonio
• John, Ellie
• Baria, Katherine
• Gibson, Isabel
• Gelmon, Karen A.

Titel

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

Ist Teil von

• Breast cancer research and treatment, 2024-04, Vol.204 (2), p.237-248

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2024

Link zum Volltext

Quelle

SpringerLink Journals

Beschreibungen/Notizen

• Purpose The interim analysis of the phase IIIb LUCY trial demonstrated the clinical effectiveness of olaparib in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC), with median progression-free survival (PFS) of 8.11 months, which was similar to that in the olaparib arm of the phase III OlympiAD trial (7.03 months). This prespecified analysis provides final overall survival (OS) and safety data. Methods The open-label, single-arm LUCY trial of olaparib (300 mg, twice daily) enrolled adults with gBRCAm or somatic BRCA-mutated (sBRCAm), HER2-negative mBC. Patients had previously received a taxane or anthracycline for neoadjuvant/adjuvant or metastatic disease and up to two lines of chemotherapy for mBC. Results Of 563 patients screened, 256 (gBRCAm, n  = 253; sBRCAm, n  = 3) were enrolled. In the gBRCAm cohort, median investigator-assessed PFS (primary endpoint) was 8.18 months and median OS was 24.94 months. Olaparib was clinically effective in all prespecified subgroups: hormone receptor status, previous chemotherapy for mBC, previous platinum-based chemotherapy (including by line of therapy), and previous cyclin-dependent kinase 4/6 inhibitor use. The most frequent treatment-emergent adverse events (TEAEs) were nausea (55.3%) and anemia (39.2%). Few patients (6.3%) discontinued olaparib owing to a TEAE. No deaths associated with AEs occurred during the study treatment or 30-day follow-up. Conclusion The LUCY patient population reflects a real-world population in line with the licensed indication of olaparib in mBC. These findings support the clinical effectiveness and safety of olaparib in patients with gBRCAm, HER2-negative mBC. Clinical trial registration Clinical trials registration number: NCT03286842